GSK-3α/β kinases and amyloid production in vivo

Authors:
  • IDIlse Dewachter
    Ilse Dewachter
  • BLBenoit Lechat
    Benoit Lechat
  • MGMaarten Gees
    Maarten Gees
  • AKAnna Kremer
    Anna Kremer
  • DDDavid Demedts
    David Demedts
  • PBPeter Borghgraef
    Peter Borghgraef
  • HDHerman Devijver
    Herman Devijver
  • SKSeb Kügler
    Seb Kügler
  • SPSatish Patel
    Satish Patel
  • JWJim R. Woodgett
    Jim R. Woodgett
  • FLFred Van Leuven
    Fred Van Leuven

Abstract
Arising from C. J. Phiel, C. A. Wilson, V. M.-Y. Lee & P. S. Klein Nature 423, 435-439 (2003) A major unresolved issue in Alzheimer/'s disease is identifying the mechanisms that regulate proteolytic processing of amyloid precursor protein (APP)[mdash]glycogen synthase kinase-3 (GSK-3) isozymes are thought to be important in this regulation. Phiel et al. proposed that GSK-3[agr], but not GSK-3[bgr], controls production of amyloid. We analysed the proteolytic processing of mouse and human APP in mouse brain in vivo in five different genetic and viral models. Our data do not yield evidence for either GSK-3[agr]-mediated or GSK-3[bgr]-mediated control of APP processing in brain in vivo.
Keywords

This publication has 13 references indexed in Scilit: